{"id":19933,"date":"2022-06-21T12:57:16","date_gmt":"2022-06-21T10:57:16","guid":{"rendered":"https:\/\/ilts.org\/?post_type=news&#038;p=19933"},"modified":"2022-06-21T12:57:16","modified_gmt":"2022-06-21T10:57:16","slug":"what-were-reading-june-2022","status":"publish","type":"news","link":"https:\/\/old.ilts.org\/news\/what-were-reading-june-2022\/","title":{"rendered":"What we\u00b4re reading&#8230; June 2022"},"content":{"rendered":"<h2>This month\u2019s key articles were selected by Ryan Chadha, Jiang Liu, Alessandra Mazzola, Johns Matthew, and Eleonora DeMartin.<\/h2>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><strong>HEPATOLOGY<\/p>\n<p><\/strong><\/p>\n<p><em>Transplantation<br \/>\n<\/em><strong>Recipient and Center Factors Associated With Immunosuppression Practice Beyond the First Year After Liver Transplantation and Impact on Outcomes <\/strong><\/p>\n<p>Background: Immunosuppression is a critical aspect of post-transplant management, yet practices at intermediate and late time points after liver transplantation (LT) are poorly characterized. <a href=\"https:\/\/journals.lww.com\/transplantjournal\/Fulltext\/9900\/Recipient_and_Center_Factors_Associated_With.79.aspx\" target=\"_blank\" rel=\"noopener\" data-cke-saved-href=\"https:\/\/journals.lww.com\/transplantjournal\/Fulltext\/9900\/Recipient_and_Center_Factors_Associated_With.79.aspx\">More<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><em>American Journal of Transplantation<\/em><\/p>\n<p><strong>Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation<\/strong><\/p>\n<p>Hereditary transthyretin-mediated (hATTR) amyloidosis, or ATTRv amyloidosis, is a progressive disease, for which liver transplantation (LT) has been a long-standing treatment. However, disease progression continues post-LT. This Phase 3b, open-label trial evaluated efficacy and safety of patisiran in patients with ATTRv amyloidosis with polyneuropathy progression post-LT. Primary endpoint was median transthyretin (TTR) reduction from baseline. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35213769\/\" target=\"_blank\" rel=\"noopener\" data-cke-saved-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35213769\/\">More<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><em>Liver International<\/em><\/p>\n<p><strong>Galectin-3 is overexpressed in advanced cirrhosis and predicts post-liver transplant infectious complications<\/strong><\/p>\n<p>Background &amp; aims:\u00a0Patients with advanced cirrhosis often have immune dysfunction and are more susceptible to infections. Galectin-3 is a \u03b2-galactoside-binding lectin implicated in inflammation, immune regulation and liver fibrosis. We aim to investigate galectin-3 expression in advanced cirrhosis and its ability to predict post-transplant infectious complications. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35635536\/\" target=\"_blank\" rel=\"noopener\" data-cke-saved-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35635536\/\">More<\/a><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><strong>SURGERY<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><em>Transplantation<\/em><\/p>\n<p><strong>Delivering siRNA Compounds During HOPE to Modulate Organ Function: A Proof-of-Concept Study in a Rat Liver Transplant Model<\/strong><\/p>\n<p>Background:\u00a0Apoptosis contributes to the severity of ischemia-reperfusion injury (IRI), limiting the use of extended criteria donors in liver transplantation (LT). Machine perfusion has been proposed as a platform to administer specific therapies to improve graft function. Alternatively, the inhibition of genes associated with apoptosis during machine perfusion could alleviate IRI post-LT. The aim of the study was to investigate whether inhibition of an apoptosis-associated gene (FAS) using a small interfering RNA (siRNA) approach could alleviate IRI in a rat LT model. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35581683\/\" target=\"_blank\" rel=\"noopener\" data-cke-saved-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35581683\/\">More<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><em>Journal of Pediatric Surgery<\/em><\/p>\n<p><strong>The impact of low recipient weight [\u2264 7kg] on long-term outcomes in 1078 pediatric living donor liver transplantations<\/strong><\/p>\n<p>Background:\u00a0infants who require liver transplantation represent a treatment challenge because chronic liver disease at this early age affects the child&#8217;s growth and development during a critical phase. The aim is to compare demographics, operative data, and long-term outcomes according to recipient weight at the time of LDLT. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35697543\/\" target=\"_blank\" rel=\"noopener\" data-cke-saved-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35697543\/\">More<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><em>Hepatobiliary and Pancreatic Diseases International<\/em><\/p>\n<p><strong>Robotic surgery and liver transplantation: A single-center experience of 501 robotic donor hepatectomies<\/strong><\/p>\n<p>Background:\u00a0Over the past two decades robotic surgery has been introduced to many areas including liver surgery. Laparoscopic liver surgery is an alternative minimally invasive approach. However, moving on to the complexity of living donor hepatectomies, the advantages of robotic versus laparoscopic approach have convinced us to establish the robotic platform as a standard for living donor hepatectomy. <a href=\"http:\/\/  https:\/\/pubmed.ncbi.nlm.nih.gov\/35613993\/\" target=\"_blank\" rel=\"noopener\" data-cke-saved-href=\"http:\/\/  https:\/\/pubmed.ncbi.nlm.nih.gov\/35613993\/\">More<\/a><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><strong>ANESTHESIOLOGY AND CRITICAL CARE<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><em>Advances in Medical Sciences<\/em><\/p>\n<p><strong>Intraoperative dialysis with the use of a mobile dialysis system during liver transplantation <\/strong><\/p>\n<p>Purpose:\u00a0Over the last few years, transplant centers have started to use various intraoperative renal replacement therapy (ioRRT) modalities during liver transplantation (LT) in patients with pre-existing renal impairment. Here, we present a study on the safety and clinical outcomes of intraoperative hemodialysis (ioHD) performed using a mobile dialysis system during LT. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35568010\/\" target=\"_blank\" rel=\"noopener\" data-cke-saved-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35568010\/\">More<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><em>Liver Transplantation<\/em><\/p>\n<p><strong>Intraoperative intracardiac thrombus in liver transplantation: A 9-year retrospective review focusing on treatment and outcomes<\/strong><\/p>\n<p>This study characterizes incidence and outcomes surrounding intracardiac thrombosis (ICT) during liver transplantation over 9 years at a single center before and after the routine use of transesophageal echocardiography (TEE). <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35447005\/\" target=\"_blank\" rel=\"noopener\" data-cke-saved-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35447005\/\">More<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><em>Diagnostics<\/em><\/p>\n<p><strong>Faster Time to Treatment Decision of Viscoelastic Coagulation Test Results through Improved Perception with the Animated Visual Clot: A Multicenter Comparative Eye-Tracking Study<\/strong><\/p>\n<p>As the interpretation of viscoelastic coagulation test results remains challenging, we created Visual Clot, an animated blood clot aiming to facilitate raw rotational thromboelastometry (ROTEM) parameters. This study investigated anesthesia personnel&#8217;s cognitive processing in managing simulated bleeding scenarios using eye-tracking technology. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35626425\/\" target=\"_blank\" rel=\"noopener\" data-cke-saved-href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35626425\/\">More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This month\u2019s key articles were selected by Ryan Chadha, Jiang Liu, Alessandra Mazzola, Johns Matthew, and Eleonora DeMartin. &nbsp; HEPATOLOGY Transplantation Recipient and Center Factors Associated With Immunosuppression Practice Beyond the First Year After Liver..<\/p>\n","protected":false},"featured_media":17241,"template":"","acf":[],"_links":{"self":[{"href":"https:\/\/old.ilts.org\/api\/wp\/v2\/news\/19933"}],"collection":[{"href":"https:\/\/old.ilts.org\/api\/wp\/v2\/news"}],"about":[{"href":"https:\/\/old.ilts.org\/api\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/old.ilts.org\/api\/wp\/v2\/media\/17241"}],"wp:attachment":[{"href":"https:\/\/old.ilts.org\/api\/wp\/v2\/media?parent=19933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}